Home › Compare › CYTO vs PLD

CYTO vs PLD: Dividend Comparison 2026

CYTO yields 666.67% · PLD yields 3.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CYTO wins by $608109.75M in total portfolio value
10 years
CYTO
CYTO
● Live price
666.67%
Share price
$0.30
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$608115.66M
Annual income
$469,561,018,816.25
Full CYTO calculator →
PLD
PLD
● Live price
3.10%
Share price
$132.18
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.91M
Annual income
$4,750,725.19
Full PLD calculator →

Portfolio growth — CYTO vs PLD

📍 CYTO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCYTOPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CYTO + PLD cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
CYTO pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CYTO
Annual income on $10K today (after 15% tax)
$56,666.67/yr
After 10yr DRIP, annual income (after tax)
$399,126,865,993.81/yr
PLD
Annual income on $10K today (after 15% tax)
$263.66/yr
After 10yr DRIP, annual income (after tax)
$4,038,116.41/yr
At 15% tax rate, CYTO beats the other by $399,122,827,877.40/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CYTO + PLD for your $10,000?

CYTO: 50%PLD: 50%
100% PLD50/50100% CYTO
Portfolio after 10yr
$304060.78M
Annual income
$234,782,884,770.71/yr
Blended yield
77.22%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

CYTO
No analyst data
Altman Z
-1.2
Piotroski
5/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+2.9% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CYTO buys
0
PLD buys
0
No recent congressional trades found for CYTO or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCYTOPLD
Forward yield666.67% ✓3.10%
Annual dividend / share$2.00$4.10 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4% ✓
Portfolio after 10y$608115.66M ✓$5.91M
Annual income after 10y$469,561,018,816.25 ✓$4,750,725.19
Total dividends collected$596792.85M ✓$5.78M
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: CYTO vs PLD ($10,000, DRIP)

YearCYTO PortfolioCYTO Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$77,367$66,666.67$11,241$540.96+$66.1K → CYTO
2$564,818$482,035.31$13,019$991.13+$551.8K → CYTO
3$3,893,246$3,288,890.67$15,801$1,870.97+$3.88M → CYTO
4$25,352,760$21,186,987.16$20,609$3,701.21+$25.33M → CYTO
5$156,070,781$128,943,327.59$29,919$7,867.97+$156.04M → CYTO
6$908,837,800$741,842,064.29$50,631$18,617.74+$908.79M → CYTO
7$5,009,769,782$4,037,313,336.56$105,528$51,352.20+$5009.66M → CYTO
8$26,159,339,258$20,798,885,591.56$287,364$174,449.42+$26159.05M → CYTO
9$129,490,317,125$101,499,824,118.87$1,081,760$774,280.77+$129489.24M → CYTO
10$608,115,658,140$469,561,018,816.25$5,908,209$4,750,725.19+$608109.75M → CYTO

CYTO vs PLD: Complete Analysis 2026

CYTO — Stock

Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It operates in Switzerland, the United States, Europe, and Australia. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. Altamira Therapeutics Ltd. was founded in 2003 and is headquartered in Hamilton, Bermuda.

Full CYTO Calculator →

PLD — REIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this CYTO vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CYTO vs SCHDCYTO vs JEPICYTO vs OCYTO vs KOCYTO vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.